Company news

Kodiak Sciences Inc news in 2025

Kodiak Sciences Inc's news releases, calls and decks from 2025, newest first.

View company

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

December 17, 2025

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

December 15, 2025

Kodiak Sciences Announces Proposed Public Offering of Common Stock

December 14, 2025

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

November 12, 2025

Kodiak Sciences to Present at Upcoming Investor Conferences

November 11, 2025

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

November 4, 2025

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

September 14, 2025

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

September 1, 2025

Kodiak Sciences to Present at American Chemical Society Fall 2025

August 18, 2025

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

August 12, 2025

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

July 9, 2025

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

June 24, 2025

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 28, 2025

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 13, 2025

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

April 30, 2025

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

March 26, 2025

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

March 9, 2025

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

February 3, 2025

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

Decks in 2025